Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK

BACKGROUND: The PI 3-kinase (PI3K) pathway has been implicated as a target for melanoma therapy. METHODS: Given the high degree of genetic heterogeneity in melanoma, we sought to understand the breadth of variation in PI3K signalling in the large NZM panel of early passage cell lines developed from...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Autores principales: Tran, Khanh B., Kolekar, Sharada, Jabed, Anower, Jaynes, Patrick, Shih, Jen-Hsing, Wang, Qian, Flanagan, Jack U., Rewcastle, Gordon W., Baguley, Bruce C., Shepherd, Peter R.
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7866738/
https://ncbi.nlm.nih.gov/pubmed/33549048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-021-07826-4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares